Company profile
Stablecoin Development Corp.
AMEX: SDEV · Healthcare · Medical - Pharmaceuticals
#636 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
44DFH 41DQ 54GM 44SS 24
v0.1 · 65/100 weight · provisional
↑ disclosure history, Piotroski F · ↓ listing tenure, workforce scale
Methodology →Revenue TTM
$4.7M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$22.1M
Employees
4
as of 2026-08-20
Market cap
$50.4M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$9.8M$9.8M2024
Net income-$22.1M-$22.1M2025
Operating income-$8.4M-$8.4M2025
Total assets$9.0M$9.0M2025
Liabilities$31.9M$31.9M2025
Equity-$23.2M-$23.2M2025
Revenue trend
FY2018 – FY2024 · USD
FY18
FY18
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Stablecoin Development Corp.’s revenue?
Stablecoin Development Corp. booked $9.8M in FY2024 revenue, contracting 34% year over year — slower than 77% of Healthcare companies we track, at a -226.4% net margin.
Peers · Healthcare
Zenas BioPharma, Inc.33DJanux Therapeutics, Inc.54DSyros Pharmaceuticals, Inc.——Taysha Gene Therapies, Inc.48DCalithera Biosciences, Inc.——Precigen, Inc.44DNeighbors
Alameda →Key facts
CEOMichael Kazley
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersEmeryville, CA
ExchangeAMEX: SDEV
Employees4
IPO date2026-04-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.